Claims
- 1-6. (canceled)
- 7. A method for detecting expression of TFI comprising:
contacting a TFI probe to a sample comprising nucleic acids; and detecting hybridization of the TFI probe to TFI nucleic acids in the sample.
- 8. The method of claim 7 wherein the TFI probe comprises cDNA encoding full-length TFI.
- 9. The method of claim 7 wherein the TFI probe comprises cDNA encoding mature TFI.
- 10. The method of claim 7 wherein the TFI probe is labeled.
- 11. The method of claim 7 wherein the TFI probe is radiolabeled.
- 12. The method of claim 11 wherein the radiolabel is 32P.
- 13. The method of claim 7 wherein the sample is polyA+ mRNA.
- 14. A method of producing an antibody to TFI comprising:
administering a TFI peptide to an animal; collecting antiserum from the animal; and isolating TFI antibody from the antiserum.
- 15. The method of claim 14 wherein the TFI peptide comprises mature TFI as shown in amino acid residues 29-304 of FIG. 3.
- 16. The method of claim 14 wherein the TFI peptide comprises amino acid residues 3-25 of mature TFI.
- 17. The method of claim 14 wherein the TFI peptide is conjugated to Keyhole limpet hemocyanin.
- 18. The method of claim 14 wherein the animal is a rabbit.
- 19. The method of claim 14 wherein the peptide is administered by intradermal injection.
- 20. The method of claim 14 wherein the step of isolating is performed by chromatography.
- 21. The method of claim 20 wherein chromatography is performed on a TFI peptide column.
- 22. The method of claim 21 wherein the column comprises a resin of Sepharose 4B.
- 23. A method for isolating TFI comprising:
culturing a liver-derived cell line in conditioned medium; and isolating TFI from the medium.
- 24. The method of claim 23 wherein the TFI is isolated from the medium by chromatography.
- 25. The method of claim 24 wherein chromatography is performed using a TFI antibody coupled to a resin.
- 26. The method of claim 25 wherein the resin is Sepharose 4B.
- 27. The method of claim 23 wherein the liver-derived cell line is a Chang liver cell line.
- 28. The method of claim 23 wherein the liver-derived cell line is a HepG2 hepatoma cell line.
- 29. The method of claim 23 wherein the liver-derived cell line is a SK-HEP-1 hepatoma cell line.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This is a continuation-in-part of copending application Ser. No. 77,366, filed Jul. 23, 1987.
Divisions (2)
|
Number |
Date |
Country |
Parent |
10377817 |
Mar 2003 |
US |
Child |
10886556 |
Jul 2004 |
US |
Parent |
07123753 |
Nov 1987 |
US |
Child |
07566280 |
Aug 1990 |
US |
Continuations (6)
|
Number |
Date |
Country |
Parent |
09627676 |
Jul 2000 |
US |
Child |
10377817 |
Mar 2003 |
US |
Parent |
09054782 |
Apr 1998 |
US |
Child |
09627676 |
Jul 2000 |
US |
Parent |
08463323 |
Jun 1995 |
US |
Child |
09054782 |
Apr 1998 |
US |
Parent |
08355351 |
Dec 1994 |
US |
Child |
08463323 |
Jun 1995 |
US |
Parent |
08093285 |
Jul 1993 |
US |
Child |
08355351 |
Dec 1994 |
US |
Parent |
07566280 |
Aug 1990 |
US |
Child |
08093285 |
Jul 1993 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
07077366 |
Jul 1987 |
US |
Child |
07123753 |
Nov 1987 |
US |